Metagenomi, Inc.
MGX
$1.56
-$0.05-2.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.91M | 33.77M | 45.26M | 52.30M | 55.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.91M | 33.77M | 45.26M | 52.30M | 55.08M |
| Cost of Revenue | 96.10M | 97.07M | 102.88M | 109.18M | 110.77M |
| Gross Profit | -65.18M | -63.30M | -57.62M | -56.88M | -55.69M |
| SG&A Expenses | 27.09M | 28.51M | 30.07M | 32.02M | 32.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.18M | 125.58M | 132.95M | 141.20M | 143.55M |
| Operating Income | -92.27M | -91.81M | -87.69M | -88.90M | -88.47M |
| Income Before Tax | -90.04M | -90.29M | -83.36M | -83.57M | -75.53M |
| Income Tax Expenses | -1.30M | -3.17M | -5.42M | -5.51M | -1.58M |
| Earnings from Continuing Operations | -88.74 | -87.12 | -77.95 | -78.06 | -73.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.74M | -87.12M | -77.95M | -78.06M | -73.95M |
| EBIT | -92.27M | -91.81M | -87.69M | -88.90M | -88.47M |
| EBITDA | -86.79M | -86.30M | -82.20M | -83.49M | -83.33M |
| EPS Basic | -2.39 | -2.35 | -2.11 | -2.62 | -7.66 |
| Normalized Basic EPS | -1.37 | -1.35 | -1.25 | -1.58 | -4.33 |
| EPS Diluted | -2.39 | -2.35 | -2.11 | -2.62 | -7.66 |
| Normalized Diluted EPS | -1.37 | -1.35 | -1.25 | -1.58 | -4.33 |
| Average Basic Shares Outstanding | 148.83M | 148.25M | 147.72M | 131.84M | 97.93M |
| Average Diluted Shares Outstanding | 148.83M | 148.25M | 147.72M | 131.84M | 97.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |